OpenAI acquires Orchestra Bio to bolster life sciences AI push

OpenAI has acquired Orchestra Bio, a startup building AI agents for pharmaceutical drug development, integrating its team and technology into its Rosalind life sciences suite. This marks a strategic expansion beyond core AI competencies into science, intensifying competition with Anthropic. The deal signals a broader trend of AI giants targeting specialized verticals, though financial terms and immediate product impact remain undisclosed.